Your browser doesn't support javascript.
PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2.
Simon, Viviana; Kota, Vamsi; Bloomquist, Ryan F; Hanley, Hannah B; Forgacs, David; Pahwa, Savita; Pallikkuth, Suresh; Miller, Loren G; Schaenman, Joanna; Yeaman, Michael R; Manthei, David; Wolf, Joshua; Gaur, Aditya H; Estepp, Jeremie H; Srivastava, Komal; Carreño, Juan Manuel; Cuevas, Frans; Ellebedy, Ali H; Gordon, Aubree; Valdez, Riccardo; Cobey, Sarah; Reed, Elaine F; Kolhe, Ravindra; Thomas, Paul G; Schultz-Cherry, Stacey; Ross, Ted M; Krammer, Florian.
  • Simon V; Department of Microbiology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.
  • Kota V; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.
  • Bloomquist RF; The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.
  • Hanley HB; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.
  • Forgacs D; Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.
  • Pahwa S; Department of Medicine, Medical College of Georgia, Augusta Universitygrid.410427.4, Augusta, Georgia, USA.
  • Pallikkuth S; Department of Restorative Sciences, Dental College of Georgia, Augusta Universitygrid.410427.4, Augusta, Georgia, USA.
  • Miller LG; Center for Vaccine and Immunology, University of Georgiagrid.213876.9, Athens, Georgia, USA.
  • Schaenman J; Center for Vaccine and Immunology, University of Georgiagrid.213876.9, Athens, Georgia, USA.
  • Yeaman MR; Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Manthei D; Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Wolf J; Department of Medicine, David Geffen School of Medicine at UCLAgrid.471398.0, Los Angeles, California, USA.
  • Gaur AH; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
  • Estepp JH; Department of Medicine, David Geffen School of Medicine at UCLAgrid.471398.0, Los Angeles, California, USA.
  • Srivastava K; Department of Medicine, David Geffen School of Medicine at UCLAgrid.471398.0, Los Angeles, California, USA.
  • Carreño JM; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
  • Cuevas F; Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
  • Ellebedy AH; Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Gordon A; Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Valdez R; Department of Microbiology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.
  • Cobey S; Department of Microbiology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.
  • Reed EF; Department of Microbiology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.
  • Thomas PG; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Schultz-Cherry S; Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Ross TM; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Krammer F; Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
mSphere ; 7(3): e0017922, 2022 06 29.
Article in English | MEDLINE | ID: covidwho-1854243
ABSTRACT
To understand reinfection rates and correlates of protection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we established eight different longitudinal cohorts in 2020 under the umbrella of the PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2)/SPARTA (SARS SeroPrevalence And Respiratory Tract Assessment) studies. Here, we describe the PARIS/SPARTA cohorts, the harmonized assays and analysis that are performed across the cohorts, as well as case definitions for SARS-CoV-2 infection and reinfection that have been established by the team of PARIS/SPARTA investigators. IMPORTANCE Determining reinfection rates and correlates of protection against SARS-CoV-2 infection induced by both natural infection and vaccination is of high significance for the prevention and control of coronavirus disease 2019 (COVID-19). Furthermore, understanding reinfections or infection after vaccination and the role immune escape plays in these scenarios will inform the need for updates of the current SARS-CoV-2 vaccines and help update guidelines suitable for the postpandemic world.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: MSphere Year: 2022 Document Type: Article Affiliation country: Msphere.00179-22

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: MSphere Year: 2022 Document Type: Article Affiliation country: Msphere.00179-22